How This Works
PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence[1]. Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells[2][6]. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal preparation[4]. No human clinical studies have been conducted, and all measurement protocols remain theoretical extrapolations from preclinical work.
References
Journal of Biomedical Science (2017)
— Review of research peptides; PNC-27 mechanism and cancer cell selectivity
Cancer Chemotherapy and Pharmacology (2010)
— PNC-27 induces tumor cell membrane lysis; preclinical mechanism study
FDA Drug Safety Communication (2015)
— Warning: PNC-27 is unapproved; safety not established
International Journal of Cancer (2006)
— PNC-28 (related peptide) blocks pancreatic cancer growth in vivo; mouse model study
Peptide Sciences
— Peptide storage guidelines: lyophilized and reconstituted stability
BMC Cancer (2008)
— PNC-27 selectively kills cancer cells via HDM-2 binding and membrane disruption
PubMed (2012)
— PNC-27 peptide induces necrosis via direct membrane lysis mechanism
CDC
— Vaccine preparation: route (angle/site guidance)
National Hemophilia Foundation (2021)
— measurement guidelines: needle length, angle, site preparation
NCBI Bookshelf
— Best practices for measurement (asepsis, preparation, and preparation)
Drug Measurement Review (PMC)
— Pharmacologic considerations of the route